Drug intelligence / Profile preview

KS1

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

KS1 is a bi- and tri-cyclic catalytic interceptor designed using lab-on-a-chip technology and artificial intelligence (double-shell deep learning) to inhibit multiple SARS-CoV-2 protomers. It is characterized by a nitrile catalytic head and specific halogen atom placement, enhancing its ability to deactivate viral protein targets. KS1 meets druglikeness criteria according to Lipinski's rule of five, GHOSE, VEBER, EGAN, and MUEGGE.

Beyond the preview

Go deeper on KS1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KS1.

Explore the full profile